The subset of ovarian cancer (OC) diagnosed ≤ 30yo represents a distinct subgroup exhibiting disparities from late-onset OC in many aspects, including indefinite germline cancer predisposition. We performed DNA/RNA-WES with HLA-typing, PRS assessment and survival analysis in 123 early-onset OC-patients compared to histology/stage-matched late-onset and unselected OC-patients, and population-matched controls. Only 6/123(4.9%) early-onset OC-patients carried a germline pathogenic variant (GPV) in high-penetrance OC-predisposition genes. Nevertheless, our comprehensive germline analysis of early-onset OC-patients revealed two divergent trajectories of potential germline susceptibility. Firstly, overrepresentation analysis highlighted a connection to breast cancer (BC) that was supported by the CHEK2 GPV enrichment in early-onset OC(p = 1.2 × 10-4), and the presumably BC-specific PRS313, which successfully stratified early-onset OC-patients from controls(p = 0.03). The second avenue pointed towards the impaired immune response, indicated by LY75-CD302 GPV(p = 8.3 × 10-4) and diminished HLA diversity compared with controls(p = 3 × 10-7). Furthermore, we found a significantly higher overall GPV burden in early-onset OC-patients compared to controls(p = 3.8 × 10-4). The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.

Centre for Medical Genetics and Reproductive Medicine GENNET Prague Czech Republic

Department of Biochemistry Faculty of Science Charles University Prague Czech Republic

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Genetics and Microbiology Faculty of Science Charles University Prague Prague Czech Republic

Department of Gynecology and Obstetrics Bulovka University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Paediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

SEER. https://seer.cancer.gov/statfacts/html/ovary.html.

Labidi-Galy SI, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 2017;8:1093. doi: 10.1038/s41467-017-00962-1. PubMed DOI PMC

Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 2019;20:952. doi: 10.3390/ijms20040952. PubMed DOI PMC

Pearce CL, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol. Biomarkers Prev. 2015;24:671–676. doi: 10.1158/1055-9965.EPI-14-1128. PubMed DOI PMC

Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin. Genet. 2019 doi: 10.1111/cge.13566. PubMed DOI PMC

Lhotova K, et al. Multigene panel germline testing of 1333 Czech patients with ovarian cancer. Cancers (Basel) 2020;12:956. doi: 10.3390/cancers12040956. PubMed DOI PMC

Stratton JF, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study. Am. J. Hum. Genet. 1999;65:1725–1732. doi: 10.1086/302671. PubMed DOI PMC

Flaum N, et al. MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1. J. Med. Genet. 2023 doi: 10.1136/jmg-2022-109055. PubMed DOI PMC

Herold N, et al. Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer. Cancer Med. 2023;12:15256–15260. doi: 10.1002/cam4.6214. PubMed DOI PMC

Carter NJ, et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol. Oncol. 2018;151:481–488. doi: 10.1016/j.ygyno.2018.09.030. PubMed DOI

Horackova K, Janatova M, Kleiblova P, Kleibl Z, Soukupova J. Early-onset ovarian cancer <30 years: What do we know about its genetic predisposition? Int. J. Mol. Sci. 2023;24:17020. doi: 10.3390/ijms242317020. PubMed DOI PMC

Bolton KL, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 2010;42:880–884. doi: 10.1038/ng.666. PubMed DOI PMC

Dareng EO, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur. J. Hum. Genet. 2022;30:349–362. doi: 10.1038/s41431-021-00987-7. PubMed DOI PMC

Goode EL, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 2010;42:874–879. doi: 10.1038/ng.668. PubMed DOI PMC

Jervis S, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J. Med. Genet. 2015;52:465–475. doi: 10.1136/jmedgenet-2015-103077. PubMed DOI PMC

Kuchenbaecker KB, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2017;109:dwj302. doi: 10.1093/jnci/djw302. PubMed DOI PMC

Permuth-Wey J, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat. Commun. 2013;4:1627. doi: 10.1038/ncomms2613. PubMed DOI PMC

Pharoah PD, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet. 2013;45:362–370. doi: 10.1038/ng.2564. PubMed DOI PMC

Phelan CM, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat. Genet. 2017;49:680–691. doi: 10.1038/ng.3826. PubMed DOI PMC

Yang X, et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J. Med. Genet. 2018;55:546. doi: 10.1136/jmedgenet-2018-105313. PubMed DOI PMC

Jia G, et al. Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers. JNCI Cancer Spectr. 2020;4:pkaa021. doi: 10.1093/jncics/pkaa021. PubMed DOI PMC

Kubler K, et al. HLA-class II haplotype associations with ovarian cancer. Int. J. Cancer. 2006;119:2980–2985. doi: 10.1002/ijc.22266. PubMed DOI

The NCMG research infrastructure; http://ncmg.cz.

National Marrow Donors Registry; www.allelefrequencies.net/pop6001c.asp?pop_id=3258

NCCN. Guidelines Version 2.2024: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, 2023).

Hovhannisyan M, et al. Polygenic risk score (PRS) and its potential for breast cancer risk stratification. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2023;36:198–205. doi: 10.48095/ccko2023198. PubMed DOI

Hovhannisyan M, et al. Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction. Cancer. 2024 doi: 10.1002/cncr.35337. PubMed DOI

Soukupova J, et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One. 2018;13:e0195761. doi: 10.1371/journal.pone.0195761. PubMed DOI PMC

Horackova K, et al. Low frequency of cancer-predisposition gene mutations in liver transplant candidates with hepatocellular carcinoma. LID - 2022 doi: 10.3390/cancers15010201. PubMed DOI PMC

Walker LC, et al. Comprehensive assessment of BARD1 messenger ribonucleic acid splicing with implications for variant classification. Front. Genet. 2019;10:1139. doi: 10.3389/fgene.2019.01139. PubMed DOI PMC

Dobin A, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. PubMed DOI PMC

https://broadinstitute.github.io/picard/.

Cotto KC, et al. Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. Nat. Commun. 2023;14:1589. doi: 10.1038/s41467-023-37266-6. PubMed DOI PMC

Agius P, Geiger H, Robine N. SCANVIS: A tool for SCoring, ANnotating and VISualizing splice junctions. Bioinformatics. 2019;35:4843–4845. doi: 10.1093/bioinformatics/btz452. PubMed DOI PMC

Fadista J, Manning AK, Florez JC, Groop L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur. J. Hum. Genet. 2016;24:1202–1205. doi: 10.1038/ejhg.2015.269. PubMed DOI PMC

Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199–W205. doi: 10.1093/nar/gkz401. PubMed DOI PMC

Wang S, et al. SpecHLA enables full-resolution HLA typing from sequencing data. Cell Rep. Methods. 2023;3:100589. doi: 10.1016/j.crmeth.2023.100589. PubMed DOI PMC

Mavaddat N, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 2019;104:21–34. doi: 10.1016/j.ajhg.2018.11.002. PubMed DOI PMC

Borde J, et al. Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers. J. Natl. Cancer Instit. 2021;113:893–899. doi: 10.1093/jnci/djaa203. PubMed DOI PMC

Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. Am J Pathol. 2016;186:733–747. doi: 10.1016/j.ajpath.2015.11.011. PubMed DOI PMC

Zemankova, P. et al. A deep intronic recurrent CHEK2 variant c.1009-118_1009-87delinsC affects pre-mRNA splicing and contributes to hereditary breast cancer predisposition. Breast 75, 103721, doi:10.1016/j.breast.2024.103721 (2024). PubMed PMC

Bonifaz L, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627–1638. doi: 10.1084/jem.20021598. PubMed DOI PMC

Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J. 2005;272:6179–6217. doi: 10.1111/j.1742-4658.2005.05031.x. PubMed DOI

Network, N. C. C. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2023), <https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf> (2022).

Casper AC, et al. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol. Oncol. 2021;162:454–460. doi: 10.1016/j.ygyno.2021.05.034. PubMed DOI

Wang J, Du Y, Kang Y. Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study. Int. J. Gynaecol. Obstet. 2024 doi: 10.1002/ijgo.15338. PubMed DOI

Kleiblova P, et al. Parallel DNA/RNA NGS using an identical target enrichment panel in the analysis of hereditary cancer predisposition. Folia Biol (Praha) 2024;70:62–73. doi: 10.14712/fb2024070010062. PubMed DOI

Koczkowska M, et al. Spectrum and prevalence of pathogenic variants in ovarian cancer susceptibility genes in a group of 333 patients. Cancers (Basel) 2018;10:442. doi: 10.3390/cancers10110442. PubMed DOI PMC

Jarhelle E, et al. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Sci. Rep. 2019;9:19986. doi: 10.1038/s41598-019-55515-x. PubMed DOI PMC

Lawrenson K, et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis. 2015;36:1341–1353. doi: 10.1093/carcin/bgv138. PubMed DOI PMC

Kurian, A. W. et al. Genetic Testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. JCO1801854, 10.1200/JCO.18.01854 (2019). PubMed PMC

Stolarova, L. et al. CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. Cells 9, doi:10.3390/cells9122675 (2020). PubMed PMC

Lo TH, et al. Characterization of the expression and function of the C-Type lectin receptor CD302 in mice and humans reveals a role in dendritic cell migration. J. Immunol. 2016;197:885–898. doi: 10.4049/jimmunol.1600259. PubMed DOI

Faddaoui A, et al. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget. 2015;7:14125. doi: 10.18632/oncotarget.7288. PubMed DOI PMC

Mehdi S, Bachvarova M, Scott-Boyer MP, Droit A, Bachvarov D. LY75 Ablation mediates mesenchymal-epithelial transition (MET) in epithelial ovarian cancer (EOC) cells associated with DNA methylation alterations and suppression of the Wnt/beta-Catenin pathway. Int. J. Mol. Sci. 2020;21:1848. doi: 10.3390/ijms21051848. PubMed DOI PMC

Pagliuca S, Gurnari C, Rubio MT, Visconte V, Lenz TL. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front. Immunol. 2022;13:944872. doi: 10.3389/fimmu.2022.944872. PubMed DOI PMC

Aureli A, et al. Breast cancer is associated with increased HLA-DRB1*11:01 and HLA-DRB1*10:01 allele frequency in a population of patients from central Italy. Immunol. Invest. 2020;49:489–497. doi: 10.1080/08820139.2020.1737539. PubMed DOI

Tsai SC, Sheen MC, Chen BH. Association between HLA-DQA1, HLA-DQB1 and oral cancer. Kaohsiung J. Med. Sci. 2011;27:441–445. doi: 10.1016/j.kjms.2011.06.003. PubMed DOI PMC

Chen PC, Tsai EM, Er TK, Chang SJ, Chen BH. HLA-DQA1 and -DQB1 allele typing in southern Taiwanese women with breast cancer. Clin. Chem. Lab. Med. 2007;45:611–614. doi: 10.1515/CCLM.2007.132. PubMed DOI

Wang QL, et al. Association of HLA diversity with the risk of 25 cancers in the UK Biobank. EBioMedicine. 2023;92:104588. doi: 10.1016/j.ebiom.2023.104588. PubMed DOI PMC

Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147:705–713. doi: 10.1016/j.ygyno.2017.10.001. PubMed DOI

Kar SP, et al. Common genetic variation and susceptibility to ovarian cancer: Current insights and future directions. Cancer Epidemiol. Biomarkers Prev. 2018;27:395–404. doi: 10.1158/1055-9965.EPI-17-0315. PubMed DOI

Struzinska I, et al. Somatic genomic and transcriptomic characterization of primary ovarian serous borderline tumors and low-grade serous carcinomas. J. Mol. Diagn. 2024 doi: 10.1016/j.jmoldx.2023.12.004. PubMed DOI

Qing T, et al. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. Nat. Commun. 2020;11:2438. doi: 10.1038/s41467-020-16293-7. PubMed DOI PMC

Chan JK, et al. Ovarian cancer in younger vs older women: A population-based analysis. Br. J. Cancer. 2006;95:1314–1320. doi: 10.1038/sj.bjc.6603457. PubMed DOI PMC

Gockley A, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet. Gynecol. 2017;129:439–447. doi: 10.1097/AOG.0000000000001867. PubMed DOI PMC

Gershenson DM, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: Results of a large single-institution registry of a rare tumor. J. Clin. Oncol. 2015;33:2675–2682. doi: 10.1200/JCO.2015.61.0873. PubMed DOI PMC

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer